CompletedNCT01175135
PF-02545920 for Acute Schizophrenia Symptoms
About this title
Read the official source — NCT01175135Researchers compared PF-02545920, placebo and Risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–65Multiple countries
Understand this study
What did researchers investigate?
Researchers compared PF-02545920, placebo and Risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 45 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 259
- Sponsor
- Pfizer
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Germany, Ukraine
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01175135
- Official title
Show the full official title
A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLittle Rock, United States · Anaheim, United States · Escondido, United States
29 more locations
- Garden Grove, United States
- Long Beach, United States
- Orange, United States
- Paramount, United States
- San Diego, United States
- Santa Ana, United States
- Torrance, United States
- Washington D.C., United States
- Bradenton, United States
- Maitland, United States
- Orlando, United States
- Atlanta, United States
- Hoffman Estates, United States
- Lake Charles, United States
- Rockville, United States
- St Louis, United States
- Willingboro, United States
- Hollis, United States
- Philadelphia, United States
- Austin, United States
- DeSoto, United States
- Houston, United States
- Kirkland, United States
- Mannheim, Germany
- Dnipropetrovsk, Ukraine
- Kyiv, Ukraine
- Luhansk, Ukraine
- Poltava, Ukraine
- Stepanivka, Kherson, Ukraine
Questions about this study
What did researchers investigate?
Researchers compared PF-02545920, placebo and Risperidone to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Pfizer.
Did this study involve medication?
Yes. The study involved medication, including PF-02545920, Placebo and Risperidone.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia